Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘CD3’

Critical Analysis of the Emerging Trispecific Landscape

Dawn of a new era or a setting sun on a tricky approach…

Three is a magic number – except when it isn’t.

Trispecific antibodies are one of the emerging stars on the multispecific stage, promising to hit not one, not two, but three targets with a single swing. It’s a tempting idea – who doesn’t love a good triple play?

With great ambition also comes great complexity, and not every design is ready for primetime.

At this year’s AACR, the trispecific party got a little louder.

From PD-1/CTLA-4/VEGF mashups to CD3-based T cell whisperers, the posters are brimming with innovation – and more than a few eyebrow-raisers.

So before we get swept up in the hype, let’s pause and ask a provocative question: is this a triple threat or a triple headache waiting to happen?

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Playing with fire

Are we playing with fire – again?

A few years ago, Dr Philippe Armand at Dana Farber used this very colourful phrase accompanied by ‘rip roaring toxicities’ when describing autoimmune type reactions his institution had seen in patients with hematologic malignancies who had received prior allo SCT (see more here).

Now we’re starting to see more evidence emerge for improved activity with next generation bispecifics accompanied by lethalities.

Finding the balance between the two is proving to be something akin to a tightrope across the Niagara Falls without a safety net.

With so many runners and riders in the IO niche, it’s often hard to tell who will be the winner

Checkpoint blockade, CAR-T cells and fusion proteins haven’t been the only ones to struggle with this challenge, since bispecifics are also an immunotherapy approach capable of inducing some potent, if unwanted immune effects.

Here we look at the challenge in the bispecific arena with a focus on some recent events…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

A review of the emerging bispecific landscape

We have come a long way from our last discussion about the bispecific antibody landscape going into the ASH20 meeting, with the current update on the field barely including any of those established agents, such is the pace of progress in less than a year!

Of course, part of difference lies in the old liquid versus solid tumour settings, where different tools or targets are needed for each one.

The good news is there are a lot of new players to look at, both private and public, emerging biotech and established pharma companies.

Some of the evolving trends which emerged from our latest analysis surprised even the seasoned observers at BSB, which is no bad thing at all.

So what’s in store from our latest in-depth review going into SITC 2021?

BSB subscribers can read up on our ongoing commentary and analysis from the cancer conference season for our meeting coverage at SITC – you can either log-in or click to access our latest analysis.

This content is restricted to subscribers

Who is winning the CD20xCD3 Bispecific Race to Market?

Virtual meetings mean we miss the fun of German pop-up sausage stands and focus solely on the new emerging clinical data!

EHA25 Virtual, Not-In-Frankfurt – There’s a lot of commercial interest in CD20 x CD3 bispecifics, and in this post we’re taking a look at some of the latest clinical data presented at recent ASCO and EHA virtual meetings. Companies mentioned include Regeneron, Roche/Genentech, Genmab/Abbvie, Xencor, and IGM Biosciences.

Any analysis of a rapidly evolving and fast-moving landscape only represents a snapshot in time at the point it was taken, and this post is not intended to be a comprehensive landscape report, you’d pay a lot more than a yearly sub to BSB for that, but we’ve been following the field, and there are some trends emerging.

What makes it interesting is there is some nuance required in the interpretation of data, and with that in mind we spoke to an investigator at the forefront of clinical research who has done trials with several of the CD20 x CD3 bispecifics in development; the insights were quite illuminating.

This post offers an update on the CD20 bispecific landscape, analysis of some of the recent data at EHA and ASCO, as well as expert opinion, what more could you ask for?

To read our latest expert interview, and gain insights from our oncology analysis and commentary around data emerging from the ASCO and EHA virtual meetings, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!